LTR Pharma (ASX:LTP) said that participants using Spontan, its intranasal erectile dysfunction product, reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activities, according to a Monday filing with the Australian bourse.

The participants also reported adverse effects such as mild-to-moderate, transient nasal discomfort and sneezing, which resolved within five minutes, the filing said.

The nasal symptoms were reduced with repeated use of the product over a two-week period, the filing added.

The company said it plans to evaluate the potential for a clinician-initiated clinical study in men with sexual performance anxiety or situational erectile difficulties in the coming year.

LTR Pharma's shares fell 6% in recent Monday trade.